Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Published:2019-07-01 Issue: Volume: Page:
ISSN:
Container-title:Clinical Trials
language:
Short-container-title:

Author:

Sequist Lecia V.,Lee Jong Seok,Han Ji-Youn,Su Wu-Chou,Yang James Chih-Hsin,Yu Helena,Ottesen Lone H.,Verheijen Remy B.,Mellemgaard Anders,Wessen Jonathan,Oxnard Geoffrey,Cho Byoung Chul

Publisher

American Association for Cancer Research

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combination of osimertinib and savolitinib as molecular inhibition of EGFR and MET receptors may be selected to provide maximum effectiveness and acceptable toxicity;Translational Lung Cancer Research;2024-06

2. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach;Lung Cancer;2024

3. Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor;Journal of Medicinal Chemistry;2023-06-21

4. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer;The Oncologist;2023-06-01

5. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer;Nature Communications;2023-02-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP